Results
|
|
15921.
|
|
|
|
15922.
|
|
|
|
15923.
|
|
|
|
15924.
|
|
|
|
15925.
|
|
|
|
15926.
|
|
|
|
15927.
|
|
|
|
15928.
|
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. [electronic resource] by
- Di Lorenzo, Giuseppe
- Autorino, Riccardo
- Giuliano, Mario
- Morelli, Emilio
- Giordano, Antonio
- Napodano, Giorgio
- Russo, Aniello
- Benincasa, Giuseppe
- D'Armiento, Massimino
- Altieri, Vincenzo
- De Placido, Sabino
Producer: 20070327
In:
Urology vol. 69
Availability: No items available.
|
|
|
15929.
|
|
|
|
15930.
|
|
|
|
15931.
|
|
|
|
15932.
|
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. [electronic resource] by
- Thiele, Sylvia
- Rauner, Martina
- Goettsch, Claudia
- Rachner, Tilman D
- Benad, Peggy
- Fuessel, Susanne
- Erdmann, Kati
- Hamann, Christine
- Baretton, Gustavo B
- Wirth, Manfred P
- Jakob, Franz
- Hofbauer, Lorenz C
Producer: 20110825
In:
Journal of cellular biochemistry vol. 112
Availability: No items available.
|
|
|
15933.
|
|
|
|
15934.
|
|
|
|
15935.
|
|
|
|
15936.
|
|
|
|
15937.
|
|
|
|
15938.
|
|
|
|
15939.
|
|
|
|
15940.
|
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. [electronic resource] by
- Brown, J P
- Roux, C
- Ho, P R
- Bolognese, M A
- Hall, J
- Bone, H G
- Bonnick, S
- van den Bergh, J P
- Ferreira, I
- Dakin, P
- Wagman, R B
- Recknor, C
Producer: 20150212
In:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA vol. 25
Availability: No items available.
|